%0 Journal Article
%T Results of 5-year follow-up study in patients with peripheral artery disease treated with PL-VEGF165 for intermittent claudication
%A Artur Isaev
%A Igor Plaksa
%A Igor Suchkov
%A Ilia Bozo
%A Ilia Staroverov
%A Nina Mzhavanadze
%A Roman Deev
%A Roman Kalinin
%A Yuriy Chervyakov
%J Archive of "Therapeutic Advances in Cardiovascular Disease".
%D 2018
%R 10.1177/1753944718786926
%X The effective treatment of chronic lower limb ischemia is one of the most challenging issues confronting vascular surgeons. Current pharmacological therapies play an auxiliary role and cannot prevent disease progression, and new treatment methods are needed. In 2011, a plasmid VEGF65-gene therapy drug was approved in Russia for the treatment of chronic lower limb ischemia (ClinicalTrials.gov identifier: {"type":"clinical-trial","attrs":{"text":"NCT03068585","term_id":"NCT03068585"}}NCT03068585). The objective of this follow-up study was to evaluate the long-term safety and efficacy of gene therapy in patients with limb ischemia of atherosclerotic genesis
%K therapeutic angiogenesis
%K gene therapy
%K VEGF165
%K intermittent claudication
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6116753/